Alyeska Investment Group
SPRY icon

Alyeska Investment Group’s ARS Pharmaceuticals SPRY Stock Holding History

Alyeska Investment Group’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-418,883
Closed -$4.88M – 737
2025
Q4 		$4.88M Buy
418,883
+28,791
+7% +$280K 0.01% 461
2025
Q3 		$3.92M Buy
390,092
+100,000
+34% +$1.44M 0.01% 472
2025
Q2 		$5.06M Hold
290,092
– – 0.02% 423
2025
Q1 		$3.65M Sell
290,092
-963,632
-77% -$11.6M 0.01% 383
2024
Q4 		$13.2M Buy
1,253,724
+1,128,724
+903% +$15.8M 0.05% 308
2024
Q3 		$1.81M Buy
+125,000
New +$1.49M 0.01% 426
2021
Q2 		– Sell
-25,000
Closed -$1.09M – 828
2021
Q1 		$1.09M Hold
25,000
– – 0.01% 550
2020
Q4 		$1.16M Buy
+25,000
New +$835K 0.02% 408

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Alyeska Investment Group's SPRY Position: Q1 2026 in Review

Alyeska Investment Group sold out of ARS Pharmaceuticals (SPRY) in Q1 2026, closing a stake of 418,883 shares — an estimated $4.88M sold.

Alyeska Investment Group first reported a position in SPRY in Q4 2020 and held it in 8 quarters. The position peaked at $13.2M in Q4 2024. 202 funds tracked by Wall St. Rank hold SPRY as of Q1 2026.

  • Alyeska Investment Group reported no remaining ARS Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Alyeska Investment Group sold 418,883 ARS Pharmaceuticals shares in Q1 2026, an estimated $4.88M.
  • Alyeska Investment Group first reported a position in ARS Pharmaceuticals in Q4 2020 and held it in 8 quarters.
  • Alyeska Investment Group's ARS Pharmaceuticals position peaked at $13.2M in Q4 2024.
  • 202 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q1 2026.

Based on Alyeska Investment Group's 13F filing for Q1 2026, filed 15 May 2026.